Skip to main content

Table 4 The efficacy and safety of standard and modified FOLFIRINOX regimen in advanced pancreatic cancer patients

From: The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

Events Standard regimen Modified regimen
Conroy et al. [5] Yoshida et al. [11] Stein et al. [14] Li et al. [15] Present study
Patients (n) 171 31 68 62 65
Disease (n)
 Locally advanced 0 0 31 0 0
 Metastatic 171 31 37 62 65
ECOG performance score (n)
 0 64 25 17 38 21
 1 106 6 20 24 38
 2 1 0 0 0 6
Dose (mg/m2)
 Oxaliplatin 85 85 85 68 65
 Irinotecan 180 150 135 135 150
 5-Fluorouracil 2400 2400 2400 2400 2400
Survival (months)
 Median OS 11.1 14.9 10.2 10.3 10.9
 Median PFS 6.4 7 6.1 7 6.7
Response (n)
 Complete response 1 0 0 0 0
 Partial response 53 12 13 13 21
 Stable disease 66 11 19 11 27
 Progressive disease 26 8 5 16 16
 Objective response rate (%) 31.6 38.7 35.1 32.5 32.3
 Disease control rate (%) 70.2 74.2 86.5 60 73.8
Adverse event (%)
 Neutropenia (grade 3/4) 45.7 83.9 12.2 29 12.4
 Fatigue (grade 3/4) 23.6 NE 12.2 0 0
 Diarrhea (grade 3/4) 12.7 6.5 16.2 0 6.2
 Vomiting (grade 3/4) 14.5 3.2 2.7 0 1.5
 Sensory neuropathy (grade 3/4) 9 9.7 2.7 0 0
 Sensory neuropathy (grade 1/2) NE 58.1 NE 0 32.3
  1. NE not evaluated